Real-world effectiveness and predictors of treatment failure for eravacycline in patients with Acinetobacter baumannii or Klebsiella pneumoniae infections: a multicenter retrospective analysis.

INTRODUCTION

Eravacycline (ERV) is a novel synthetic fluorocycline antibiotic with broad-spectrum antibacterial efficacy against pathogens. This study aimed to investigate the clinical effectiveness of eravacycline and its correlation with minimum inhibitory concentrations (MICs) against infections caused by Acinetobacter baumannii or Klebsiella pneumoniae.

METHODS

This retrospective multicenter study investigated the real-world use of ERV in 1,796 adults with infection caused by A. baumannii or K. pneumoniae in China. Antimicrobial susceptibility of strains and laboratory test results during treatment were analyzed. Microbiological and clinical outcomes were assessed at the end of treatment and day 30.

RESULTS

The overall susceptibility rate to ERV was 96.0% (1,027/1,070), and around 98% of carbapenem-resistant isolates were susceptible to ERV. ERV had a 4-fold lower MIC90 than tigecycline against both pathogens. At end of treatment, treatment success (microbiological eradication or clinical resolution) occurred in 82.6% (1,483/1,796) of the cohort with microbiological eradication achieved 76.1% (789/1,037). At day 30, infection cure was achieved in 83.57% (1,501/1,796) of the cases. Different ERV regimens (monotherapy or concomitant therapy) had no influence on the treatment and 30-day clinical outcomes. Multivariable analysis identified that elevated C-reactive protein (CRP) levels during treatment, bloodstream infection, sepsis and specific clinical interventions (e.g., central venous catheterization) were independent predictors of treatment failure.

CONCLUSIONS

The study highlights ERV's utility in infection of A. baumannii or K. pneumoniae, especially carbapenem-resistant strains.